Lecanemab is the first drug proven to slow the progression of Alzheimer's. Its manufacturer Eisai calculated its societal value to determine a suitable price.
CNFs are the new ideal material: light yet durable fiber, made from wood material and associated with sustainability, decarbonization, and low environmental impacts.
